Sealing The Deal: Skadden Splits Diabetes Drug Alliance
When Amylin Pharmaceuticals Inc.'s joint marketing agreement for a diabetes drug with Eli Lilly & Co. went sour this spring, the parties' lawyers devised a unique solution: They terminated the collaborative...To view the full article, register now.
Already a subscriber? Click here to view full article